DPM Blogs

Why A Sports Medicine Practice Is A Golden Opportunity

Doug Richie Jr. DPM FACFAS
11/5/10 | 2988 reads | 1 comments
Every day, I access a popular podiatric list serve and read numerous submissions from my colleagues who lament about their declining enthusiasm to continue practicing podiatric medicine. Many feel “helpless” as third party payors make regular cuts in reimbursement for services rendered. Others complain about the lack of ”parity” in training, scope of practice and acceptance in the community of podiatric physicians in comparison with our MD counterparts. Read More.

Recognizing And Treating Nail Trauma Caused By Ill-Fitting Shoes

Tracey Vlahovic DPM
11/3/10 | 4400 reads | 1 comments
When I think of Lady Gaga, besides the mental image of the “meat dress” and the like, I can’t help but ponder those incredible, unwearable feats of fashion engineering known as the “Armadillo” shoes by the late, great Alexander McQueen (see http://www.vogue.co.uk/blogs/the-vogue-blog/articles/091026-alexander-mc... ). Read More.

Online Shoe Shopping: Can It Be Beneficial For Patients?

Jenny L Sanders DPM
11/2/10 | 3048 reads | 0 comments
For many patients, online shoe shopping can be easier than going to a retail store. Two of my favorite sites are www.zappos.com and www.endless.com. I especially like these sites because they offer free shipping both ways, deliver the shoes within two days to one week and credit card reimbursements are easy and painless. Read More.

Can Practicing EBM Help Protect You From Malpractice Claims?

Kathleen Satterfield DPM FACFAOM
10/29/10 | 2550 reads | 2 comments
When a DPM is facing a jury preparing to decide his or her fate in a malpractice trial, the podiatrist would probably have paid a lot more attention to evidence-based medicine (EBM) protocols if the DPM had realized that the outcome of the trial would have depended on whether he or she had used EBM. Read More.

Rising Incidence Of PAD Should Spur Greater Diagnostic Vigilance And Multidisciplinary Cooperation

David G. Armstrong DPM PhD MD
10/26/10 | 2690 reads | 0 comments
Evidence continues to mount that the incidence of peripheral arterial disease (PAD) is a devastating complication of diabetes. In the United States, PAD afflicts 2 million to 3.7 million people with diabetic foot ulcers (DFU), according to an analysis published by the Sage Group.1 The group adds that approximately 1 million patients with DFUs suffer from critical limb ischemia. Read More.

Can We Achieve The ‘Equality’ In Surgery That We Have Achieved In Wound Care And Diabetic Limb Salvage?

Allen Jacobs DPM FACFAS
10/21/10 | 3114 reads | 3 comments
In the last several months, I have had the opportunity to attend four major wound care conferences. Standing in the back of the room at the Diabetic Limb Salvage conference, world famous researchers and academicians Peter Sheehan, MD, and Andrew Boulton, MD, commented to me how wonderful this meeting and others such as the American Professional Wound Care Association (APWCA) meeting had become in educating medical professionals on limb salvage. Read More.

Orthoses And Basketball Players: What I Have Learned Over The Past 15 Years

Patrick DeHeer DPM FACFAS
10/20/10 | 6980 reads | 0 comments
Basketball season has begun and for many podiatric physicians across the country, this will mean players of all ages and skill levels coming in for acute post-injury treatment and preventative care. Read More.

Are We Overly Cautious When It Comes To Trying The New Surgical ‘Stuff’?

Ron Raducanu DPM FACFAS
10/18/10 | 2283 reads | 2 comments
During residency, I was exposed to a lot of newer techniques and technology. Well, they were new back then. It was an exciting time. Not only was I learning the art of foot and ankle surgery, some of my attendings were really on the cutting edge and did not shy away from trying the latest techniques and the newest “toys” so to speak. Read More.

Ceftaroline: A New Agent For cSSSIs?

Warren S. Joseph DPM FIDSA
10/12/10 | 3329 reads | 0 comments
For a number of years, many felt that ceftobiprole would be the first of the new so-called “fifth-generation” of anti-methicillin Staphylococcus aureus (MRSA) cephalosporins. This drug, a joint venture by the Swiss company Basilea Pharmaceutica and Johnson & Johnson, had come under some fire from the Food and Drug Administration (FDA) and now looks like it has pretty much been abandoned, at least here in the United States. Read More.